Sales and Operating Profit Growth: Novo Nordisk reported 18% sales growth and 29% operating profit growth in the first half of 2025 compared to the same period in 2024. However, the company has lowered its full-year sales outlook to 8%-14% growth at constant exchange rates, reflecting lower expectations for the second half predominantly due to anticipated slower growth for Wegovy and Ozempic, two key products in the U.S. markets.

Wegovy and Ozempic Performance: Wegovy generated a 37% sales increase in U.S. operations, supported by increased prescription volumes but affected by lower realized prices. The ongoing issue of compounding GLP-1 alternatives continues to impact sales growth. The company's strategic adjustment to CVS formulary changes is expected to positively influence prescription volumes, but early indicators are showing a lower-than-expected penetration in the cash channel.

International Operations Growth: International operations grew by 19%, driven primarily by GLP-1 products. Obesity care sales in international markets were particularly strong, increasing by 125%, showing that while U.S. growth faces challenges, international markets present significant opportunities for expansion.